ESMO Media Releases

The ESMO Sarcoma and Rare Cancers Congress 2025, to be held from 20-22 March in Lugano, Switzerland, will be the convergence point for world-renowned experts to present and discuss developments in the diagnosis and treatment of rare solid tumours, going through their peculiar biology and molecular classification, while also addressing the methodological, organisational, and policy challenges that characterise this oncological area and its high unmet needs

The ESMO Targeted Anticancer Therapies Congress 2025 will showcase state-of-the-art and the latest advancements in new drug development, with focus on new targets, tumour-agnostic drug development, the role of artificial intelligence in drug development, radiotheranostics and cell therapies for solid tumours

The ESMO Immuno-Oncology Congress 2024 will take place in Geneva, Switzerland, from December 11-13, with an option to attend virtually. Leading experts will present and discuss the research advancements in the rapidly evolving field of immuno-oncology

The ESMO Asia Congress 2024 is the annual event dedicated to multidisciplinary oncology in the Asian region

The Molecular Analysis for Precision Oncology Congress 2024 (MAP) is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics

Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at ESMO 2024

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumour activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers

The ESMO Congress 2024 taking place 13-17 September in Barcelona, Spain, offers a comprehensive view of the current drug development landscape, with existing medicines demonstrating benefit in additional applications and new agents emerging in large numbers as the range of potential molecular targets for therapy continues to expand

The ESMO Congress 2024 will hold a press conference to introduce and discuss the “Eyes to the Future” Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.

The European Society for Medical Oncology (ESMO) is calling on all actors of the oncology community to commit to improving the well-being of the cancer workforce and join in 11 actions outlined in a paper published today in ESMO Open

According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation (an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer), do not face an increased risk of recurrence or developing new breast cancers

The ESMO Congress 2024 will take place from September 13-17 in Barcelona, bringing together participants from all over the world